PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Remarkably, many of these patients are highly responsive to checkpoint blockade treatment (Diaz and Le, 2015; Le et al., 2017; Le et al., 2015) where the tumor infiltrating CD8+ cytotoxic T cells can be reactivated by anti-PD1 antagonists to effectively eradicate tumors.”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Diaz and Le, 2015
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Inactivation of the Type II TGF-β Receptor in Colon Cancer Cells with Microsatellite Instability
Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., Vogelstein, B., et al. (1995) · Science · doi:10.1126/science.7761852 · Cited by 2,270
Liquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
Epitope Landscape in Breast and Colorectal Cancer
Segal, N. H., Parsons, D. W., Peggs, K. S., Velculescu, V., Kinzler, K. W., Vogelstein, B., & Allison, J. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3095 · Cited by 416
Goldstein, J., Tran, B., Ensor, J., Gibbs, P., Wong, H. L., Wong, S. F., Vilar, E., Tie, J., Broaddus, R., Kopetz, S., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu100 · Cited by 288
Cited by
Items 301–400 of 435
Liu, X. K., Feng, T., Yang, X., Chen, Z., Pan, Q., Liang, J., Fang, S., Chao, H., & Pan, Y. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.3918717 · Cited by 6
Cancer immunotherapy: new applications in urologic oncology
Mullane, S. A., & Bellmunt, J. (2016) · Current Opinion in Urology · doi:10.1097/mou.0000000000000337 · Cited by 6
Wang, Y., Jin, B., Zhou, N., Sun, Z., Li, J., Chen, Q., Wu, X., Zhou, Y., Shi, Y. X., Lu, X., et al. (2020) · Current Cancer Drug Targets · doi:10.2174/1568009620999200918121456 · Cited by 5
FALCO, E. D., Pacini, L., Bastianelli, D., Spinelli, G. P., Spoto, C., Veltri, E., & Calogero, A. (2021) · Diagnostics · doi:10.3390/diagnostics11040659 · Cited by 8
Jiang, D., Song, Q., Wei, X., Yu, Z., Liu, Y., Wang, H., Wang, X., Huang, J., Su, J., Hong, Y., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.897527 · Cited by 6
Guo, Y., Chang, G., Wan, R., Zhang, X., Ma, Z., Bai, H., & Wang, J. (2024) · Journal of Cancer · doi:10.7150/jca.93975 · Cited by 5
Yang, W., Li, Z., Li, Y., He, W., & Yan, J. (2024) · ACS Nano · doi:10.1021/acsnano.4c05893 · Cited by 7
Exploring the role of immunotherapy in the management of follicular cell-derived thyroid cancer
Benson, P., & Abdel-Rahman, O. M. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2455922 · Cited by 5
Circulating cytokeratin-positive cells and tumor budding in colorectal cancer
Märkl, B., Wilhelms, N., Anthuber, M., Schenkirsch, G., Schlimok, G., & Oruzio, D. V. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i6.433 · Cited by 5
Tian, C., Wang, X.-H., & Zhang, S. (2023) · PubMed Central · Cited by 14
He, Q., Shi, X., Yan, J., Wu, M., Gu, C., & Yu, X. (2024) · Molecular and Clinical Oncology · doi:10.3892/mco.2024.2727 · Cited by 5
Identification roles of NFE2L3 in digestive system cancers
Li, F., & Wen, Z.-L. (2023) · bioRxiv · doi:10.1007/s00432-024-05656-y · Cited by 4
PMS2 germline mutation c.943C>T (p.Arg315*)‐induced Lynch syndrome‐associated ovarian cancer
Guo, X. Q., Wu, W., Gao, H., Li, X., He, Q., Zhu, Y., & Liu, N. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.721 · Cited by 5
“Therefore, PD‐1/PD‐L1 inhibitors may benefit for the patients with dMMR MSI tumors (Lee & Le, 2016; Poliak & Indeikin, 1969), such as this proband.”
BackgroundThe potentiality of immunotherapy for sarcomas: a summary of potential predictive biomarkers
Liang, J., Chen, D., Chen, L., She, X., Zhang, H., & Xiao, Y. (2020) · Future Oncology · doi:10.2217/fon-2020-0118 · Cited by 7
Stage IIIC endometrial cancer review: Current controversies in adjuvant therapy
Buras, A. L., Mallen, A. R., Wenham, R. M., & Montejo, M. E. (2021) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2021.100754 · Cited by 6
Specimen Considerations in Molecular Oncology Testing
Gan, Q., & Roy‐Chowdhuri, S. (2022) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2022.04.002 · Cited by 5
Tran, D. T., Nguyen, B. Q. T., Nguyen, H. T., Pham, T. M. Q., Nguyen, D. V. L., Nguyen, T. N., Ho, T. K. C., Nguyen, V., Nguyen, P. T. D., Tran, D. H., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1686224 · Cited by 4
Wang, R., Liu, G., Wang, K., Pan, Z., Pei, Z., & Hu, X. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1515681 · Cited by 4
Xu, C., & Cao, W. W. (2022) · Journal of Oncology · doi:10.1155/2022/3744466 · Cited by 4
Cai, S., Sun, Z., Yan, Y., Li, W., & Wu, Q. (2023) · Immunotherapy · doi:10.2217/imt-2023-0096 · Cited by 5
Microsatellite Instability May Predict Response to Sipuleucel-T in Patients With Prostate Cancer
Zhang, K. J., Schneider, B. P., & Albany, C. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.03.016 · Cited by 4
Heo, Y. J., Kang, S. Y., Kim, S. T., Kang, W. K., Lee, J., & Kim, K.-M. (2019) · Precision and Future Medicine · doi:10.23838/pfm.2019.00079 · Cited by 4
Tian, C., Wang, Y., & Song, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.878219 · Cited by 4
Relationship of microsatellite instability to mismatch repair deficiency in malignant tumors of dogs
Inanaga, S., Igase, M., Sakai, Y., Hagimori, K., Sunahara, H., Horikirizono, H., ITAMOTO, K., Baba, K., Ohsato, Y., & Mizuno, T. (2022) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.16454 · Cited by 5
Immune checkpoint inhibition: a future guided by radiology
Khan, F., Jones, K. I., & Lyon, P. C. (2023) · British Journal of Radiology · doi:10.1259/bjr.20220565 · Cited by 4
Zhu, J., Xu, X., Jiang, M., Yang, F., Mei, Y., & Zhang, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1145380 · Cited by 5
NovumRNA: Accurate prediction of non-canonical tumor antigens from RNA sequencing data
Außerhofer, M., Rieder, D., Facciolla, M., Gronauer, R., Lamberti, G., Lisandrelli, R., Pellegatta, S., Trajanoski, Z., & Finotello, F. (2025) · iScience · doi:10.1016/j.isci.2025.113448 · Cited by 3
Immunotherapy for precision medicine in colorectal cancer
Cao, M., Xu, M. Y., Bairmani, Z. A., Bashir, B., Waldman, S. A., & Snook, A. E. (2025) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2025.2560303 · Cited by 3
“In two clinical trials, significant ORRs were achieved with the pembrolizumab treatment [76,77].”
Figaroa, O., Spaanderman, I. T., Goedegebuure, R. S. A., Cirkel, G. A., Jeurissen, F. J. F., Creemers, G. J., Bins, A. D., Tuynman, J. B., & Buffart, T. E. (2025) · BJC Reports · doi:10.1038/s44276-025-00171-0 · Cited by 3
Lucantonio, L., Schiano, L., Sozio, F., Kosta, A., Peruzzi, G., Molfetta, R., Pietropaolo, G., Laffranchi, M., Campese, A. F., Bernardini, G., et al. (2026) · OncoImmunology · doi:10.1080/2162402x.2026.2674362 · Cited by 3
Qiu, S., Li, S., Chen, Y., Ma, X., Fu, H., & Zhao, B. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102886 · Cited by 4
“Unlike MSI-H tumors, which are characterized by high tumor mutational burden (TMB), abundant neoantigen generation, and pre-existing T-cell infiltration, MSS tumors typically display an immune-excluded or immune-desert phenotype with low baseline immunogenicity [185].”
Precision Cancer Trials With Immunomodulatory Agents: Personalizing Histology Agnostic Approaches
Baretti, M., & Azad, N. S. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000390 · Cited by 4
Kim, S., Han, D., Lee, S.-Y., Moon, Y., Kang, S. J., & Kim, T. (2024) · Genes · doi:10.3390/genes15060770 · Cited by 3
Wang, X., Ni, H., Zhu, L., Huang, H., Deng, A., Hu, J., Cai, W., & Li, J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1527249 · Cited by 3
“Such patients are likely to benefit from anti-PD-1/PD-L1/CTLA-4 treatments (21–23).”
Luo, Y., Li, H., Fang, H., Gong, T., Zhao, Y., Cao, W., Yu, M., Wang, T., Lin, H., & Zhong, M. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf040 · Cited by 4
Tian, C., Liu, S., & Huo, R. (2023) · Scientific Reports · doi:10.1038/s41598-022-22259-0 · Cited by 3
Wang, R., Liu, N., Li, G., Liu, J., Ma, X., Liu, X., & Li, J. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1160599 · Cited by 3
The Implication of Liquid Biopsy in the Non-small Cell Lung Cancer: Potential and Expectation
Ren, J., & Liu, R. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3346-5_10 · Cited by 3
Tumor molecular signatures: bridging the bench and the operating room.
Nomikos, I., Kosmas, C., & Gkretsi, V. (2025) · American Journal of Surgery · doi:10.1016/j.amjsurg.2025.116393 · Cited by 3
Immunotherapy Success for Microsatellite Stable Colorectal Cancers—Searching for the Horizon
Lou, E. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.7786 · Cited by 3
Xu, X., Fa, L., Sun, X., Yang, F., Liu, Y., Song, J., Zhao, Y., & Dong, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1499580 · Cited by 2
Chang, H.-Y., Chen, J.-Y., Ke, T.-W., Jiang, Y.-W., Hong, W.-Z., Tsai, Y.-Y., Chiang, S., Lin, Y., Huang, C.-H., Chen, T.-H., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01290-8 · Cited by 2
Koustas, E., Trifylli, E.-M., Oraiopoulos, V., Karamouzis, M. V., & Sarantis, P. (2026) · Genes · doi:10.3390/genes17060674 · Cited by 3
“A substantial body of research has shown that patients with MSS/pMMR mCRC do not benefit from immune checkpoint inhibitor (ICI) monotherapy [33,34].”
The Role of Hereditary Factors in Ovarian Carcinoma
Schrader, K. A. (2017) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000319 · Cited by 3
Molecular Oncology in Management of Colorectal Cancer
Vemala, R. N. G., Katti, S. V., Sirohi, B., Manikandan, D., & Nandakumar, G. (2021) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-021-01289-6 · Cited by 2
Gu, L., Jiang, C., Xu, C., Liu, Y., & Zhou, H. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.828415 · Cited by 3
“Recent research has demonstrated that immunotherapy could be beneficial for colon cancer patients who have DMMR/MSI-H (Asaoka et al., 2015; Overman et al., 2017), and the benefit is not obvious inMSS/MSI-L patients.”
Mulder, K. E., Lim, H. J., Ravi, D., Ahmed, S., Brunet, B., Davies, J. M., Doll, C., Dueck, D.-A., Gordon, V. L., Hebbard, P. C., et al. (2022) · Current Oncology · doi:10.3390/curroncol29050257 · Cited by 2
Molecular pathology as basis for timely cancer diagnosis and therapy
Mackinnon, A. C., Chandrashekar, D. S., & Suster, D. I. (2023) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-023-03707-2 · Cited by 5
He, C., Dong, W., Lyu, Y., Qin, Y., Zhong, S., Jiang, X., & Xiao, J. (2024) · Oncology Letters · doi:10.3892/ol.2024.14835 · Cited by 2
Immunotherapy in Cervical Cancer: An Evolutionary Paradigm in Women's Reproductive Health
Damani, M., Mhaske, A. S., Dighe, S., & Sawarkar, S. P. (2025) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2025044498 · Cited by 3
Huang, Q., Zheng, X., & Xu, W. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1553380 · Cited by 2
Zhong, W., Wang, P., Wang, J., Zhu, Y., Chen, L., Qian, Y., Huang, X., & Ye, K. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102045 · Cited by 4
“LS-CRC is therefore more susceptible to ICI immunotherapy [26].”
Are There, or Shall We Discover, Biomarkers to Guide PD-1 Inhibition?
Ascierto, P. A., & de Mello, R. A. (2016) · Immunotherapy · doi:10.2217/imt-2016-5000 · Cited by 2
Immuntherapie in der Onkologie
Füreder, T. (2017) · Wiener klinische Wochenschrift Education · doi:10.1007/s11812-017-0089-1 · Cited by 2
Universal Tumor Screening for Lynch Syndrome
Hampel, H., Pearlman, R., & Cragun, D. L. (2018) · Springer eBooks · doi:10.1007/978-3-319-74259-5_17 · Cited by 2
DNA Damage Response Genes in Osteosarcoma
Tang, Y., Liu, Y., Huang, X., & Li, P. (2021) · Journal of Oncology · doi:10.1155/2021/9365953 · Cited by 2
RetractedChemotherapy in Pancreatic Ductal Adenocarcinoma
Lee, H. S., Park, S. W., & Song, S. Y. (2022) · Springer eBooks · doi:10.1007/978-981-19-0063-1_20 · Cited by 1
Zhang, D., & Chen, T. (2025) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-025-01181-4 · Cited by 1
Dong, L., Zhang, S., Wuri, Q., Qu, X., Zhang, K., Cai, Z., Qiao, Y., Feng, M., Wang, C., Wu, H., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0333 · Cited by 1
Artificial Intelligence and Cancer Immunotherapy
Shah, A., Bhat, A. A., Bhat, M. R., Assad, A., & Macha, M. A. (2025) · Springer eBooks · doi:10.1007/978-981-96-8176-1_16 · Cited by 1
DNA damage response and its clinical implications in pediatric cancers
Zhang, Y., Teng, J.-Y., Chen, X., & Zhou, B. S. (2025) · DNA repair · doi:10.1016/j.dnarep.2025.103906 · Cited by 2
Wan, D., Qi, Y., Kang, Y., Liang, F., Wang, Q., Zhang, H., Zhang, S., & Liang, X. X. (2026) · RSC Medicinal Chemistry · doi:10.1039/d5md00834d · Cited by 1
Wei, J., Zhang, R., Li, J., Li, S., Yan, X., Chen, H., Guo, H., Hu, B., Liu, Z., Guo, J., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag050 · Cited by 2
Xiao, Y.-Y., Yang, Y., Qiu, H., Yang, J., Liang, H., Jiang, Z., Tong, X., Li, Y., Huang, Q., Wu, J., et al. (2026) · Advanced Science · doi:10.1002/advs.75559 · Cited by 1
Liu, X. K., Feng, T., Yang, X., Chen, Z., Pan, Q., Liang, J., Fang, S., Chao, H., & Pan, Y. (2026) · Angewandte Chemie · doi:10.1002/ange.3918717 · Cited by 1
Yang, W., Dong, Z., Xiong, Q., Ren, Y., Zhang, L., Liu, Y., Han, J., Tian, T., Su, X., Shi, G., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.06.001 · Cited by 1
Abdelaziz, I., Allal, B.-E., Djerdjouri, B., & Bounaama, A. (2026) · Functional & Integrative Genomics · doi:10.1007/s10142-026-01983-0 · Cited by 1
Biomarkers of colorectal cancer: A genome-wide perspective
Muñoz-Galván, S., & Santos-Pereira, J. M. (2016) · Cancer translational medicine · doi:10.4103/2395-3977.196911 · Cited by 1
Nassar, A. H., Lundgren, K. T., Kim, J., Choueiri, T. K., Sonpavde, G., Kwiatkowski, D. J., & Joaquim Bellmunt, B. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00117 · Cited by 1
Research Strategies for Low-Survival Cancers
Conway, C., Collins, D. M., McCann, A. H., & Dean, K. A. (2021) · Cancers · doi:10.3390/cancers13030528 · Cited by 1
Molecular targets in GI malignancies – A pathologist's perspective
Sharma, A., & Pawar, S. (2021) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_1239_20 · Cited by 1
Wang, F., Wang, F., Sun, K., Jiang, C., Peng, S., Xu, L., Kuang, M., Guo, G., & Chen, S. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s364303 · Cited by 1
Challenges to addressing the unmet medical needs for immunotherapy targeting cold colorectal cancer
Jeong, K. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i2.215 · Cited by 2
Huang, T., Leung, B., Huang, Y., Price, L., Gui, J., & Lau, B. W. (2024) · PLoS ONE · doi:10.1371/journal.pone.0292375 · Cited by 1
Zhang, Y., Guan, H., Liu, S., Li, H., Bian, Z., He, J., Zhao, Z., Qiu, S., Mo, T., Zhang, X., et al. (2025) · eLife · doi:10.7554/elife.103559 · Cited by 2
“The development of immune checkpoint inhibitors (ICIs) transforms cancer immunotherapy ( Asaoka et al., 2015 ).”
Uppaluri, R., Bell, R. B., & Sunwoo, J. B. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.05.004
Goldstein, J. B., Tang, C. Z., Hess, K. R., Hong, D. S., Subbiah, V., Jankú, F., Fu, S., Karp, D. D., Naing, A., Tsimberidou, A. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19897
Ahn, J. H., Lee, H. Y., Kang, D. H., Song, G. J., Ahn, T. S., Son, M. W., Lee, M. S., & Baek, M. J. (2017) · Korean Journal of Clinical Oncology · doi:10.14216/kjco.17020
Microbiome and Cancer Immunotherapy
Hong, M., & Jung, M. (2021) · Korean Journal of Medicine · doi:10.3904/kjm.2021.96.4.312
Cancer of Unknown Primary: Diagnosis and Treatment
Kim, Y. S., & Lee, S. I. (2021) · Korean Journal of Medicine · doi:10.3904/kjm.2021.96.5.408
Clinical Application of Circulating Tumor DNA Analysis
Won, D., Heo, J., Kim, H., Shin, S., & Lee, S. (2022) · Laboratory Medicine Online · doi:10.47429/lmo.2022.12.4.235
Genetische Analysen beim mRCC: Zunehmendes Interesse an Präzisionsonkologie in der Urologie
Marcon, J., & Stief, C. G. (2022) · Uro-News · doi:10.1007/s00092-022-5502-0
Adenocarcinoma of the uterine corpus and sarcomas of the uterus
Eskander, R. N., Miller, D. S., Powell, M. A., & Creasman, W. T. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-77684-4.00014-3
Chun, H. J., Park, S. J., Lim, Y. J., & Song, S. Y. (2023) · Springer eBooks · doi:10.1007/978-981-99-0815-8_51
王, 承. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.13122626
Mahmud, M., Munjal, A., Savani, M., Win, H., Rozell, U., & Arshad, J. (2024) · Foregut The Journal of the American Foregut Society · doi:10.1177/26345161241238748
Lü, Z., Chen, H., Jiao, X., Wang, Y., Wu, L., Sun, H., Li, S., Gong, J., Li, J., Zou, J., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16928613
Advances in the Molecular Mechanisms in Gastrointestinal Tumorigenesis and Treatment
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-5481-4
Cancer precision medicine: Focus on gastrointestinal cancer
Pourali, G., Rajabloo, Y., Hosseini, N., Maftooh, M., Ghayour‐Mobarhan, M., Soleimanpour, S., Hassanian, S. M., Ferns, G. A., Kiani, M. A., Khazaei, M., et al. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85661-4.00006-8
Zhang, Y., Guan, H., Liu, S., Li, H., Bian, Z., He, J., Zhao, Z., Qiu, S., Mo, T., Zhang, X., et al. (2025) · eLife · doi:10.7554/elife.103559.3
Biomarkers in Immune Checkpoint Inhibitor Cancer Treatment
Papageorgiou, A. (2024) · Premier journal of science. · doi:10.70389/pjs.100023
Jeromy, H., & Gaskill, P. J. (2024) · iDEA - Drexel University Institutional Repository · doi:10.17918/00010664
Wang, S., Yu, Z., Xu, P., & Zhang, C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.13.623354
Immunotherapies in Biliary Tract Cancers: The Current Landscape
Yin, C., Alqhatani, A., & He, A. R. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_222-1
Zhang, Y., Guan, H., Liu, S., Li, H., Bian, Z., He, J., Zhao, Z., Qiu, S., Mo, T., Zhang, X., et al. (2025) · eLife · doi:10.7554/elife.103559.1
Gong, P., Li, J., Zhang, Y., & Zhang, S. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673354860250220065131
Zhang, Y., Guan, H., Liu, S., Li, H., Bian, Z., He, J., Zhao, Z., Qiu, S., Mo, T., Zhang, X., et al. (2025) · eLife · doi:10.7554/elife.103559.2
Zhang, Y., Guan, H., Liu, S., Li, H., Bian, Z., He, J., Zhao, Z., Qiu, S., Mo, T., Zhang, X., et al. (2025) · eLife · doi:10.7554/elife.103559.1.sa3
Drug-induced mismatch repair deficiency: Mixed prospects
He, Y., Wu, H., & Wang, F. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.05.004
Metadata
- Authors
- Asaoka, Y., Ijichi, H., & Koike, K.
- ORCID
- Hideaki Ijichi
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-12
- Volume
- 373
- Issue
- 20
- Pages
- 1979-1979
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2597802455
- Cited by
- 426
- References
- 3
- Citations by year
- 2026: 29 · 2025: 39 · 2024: 31 · 2023: 52 · 2022: 46 · 2021: 52 · 2020: 60 · 2019: 45 · 2018: 24 · 2017: 30 · 2016: 18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- anti-PD-1 therapy, mismatch repair deficiency, cancer immunotherapy, immune checkpoint inhibitors, microsatellite instability, Lynch syndrome, tumor immunology
- MeSH terms
- Antineoplastic Agents, Female, Humans, Male, Neoplasm Metastasis, DNA Mismatch Repair, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.